索拉芬尼与或没有对肝细胞癌的辅助干预
Shanshan Chen1, Jian Ping Liu2, Xinyu Li1
1Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
The Cochrane database of systematic reviews
|June 26, 2025
概括
本综述评估了索拉费尼布对成人肝细胞癌的治疗. 它将sorafenib与其他治疗或没有其他治疗进行比较,与安慰剂或没有干预进行比较,以了解其益处和危害.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 肝细胞癌 (HCC) 是一种具有重大全球影响的原发性肝癌.
- 索拉费尼布是一种已批准用于高级HCC的向疗法,但其疗效和安全性需要持续评估.
研究的目的:
- 系统地审查索拉费尼布在患有肝细胞癌的成年人中的有益和有害影响.
- 为了比较sorafenib,有或没有辅助干预,与安慰剂,没有干预或相同的辅助干预.
主要方法:
- 这是柯克伦审查的协议,遵循严格的系统审查方法.
- 该审查将综合随机对照试验和其他相关研究设计的证据.
主要成果:
- 证据综合正在等待审查完成.
- 预期的结果将量化索拉费尼布在HCC治疗中的疗效和安全性.
结论:
- 这些发现将为在肝细胞癌中使用索拉费尼布的临床决策提供信息.
- 本综述旨在为管理HCC的患者和医疗保健提供者提供高质量的证据.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Renal Failure: Dose Adjustments
166
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
166
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Hepatic Drug Excretion: Influencing Factors
234
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
234
Antihypertensive Drugs: Direct Renin Inhibitors
845
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
845


